ABBV - Latest News
AbbVie Inc. (ABBV), operates in Healthcare / Drug Manufacturers - General, trades on NYSE.
Market capitalization stands near $368.38B. Trailing twelve-month P/E ratio is 101.64. Beta to the broader market is 0.30.
The article list below shows the most recent ABBV headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent ABBV Headlines
Which Pharma Giant Offers Better Growth: AstraZeneca or AbbVie?
zacks.com - May 15, 2026
AZN and ABBV both boast strong drug pipelines and growth outlooks, but differences in valuation, dividends and LOE risks set them apart.
How Important Are Skyrizi and Rinvoq to AbbVie's Q1 Results?
zacks.com - May 15, 2026
ABBV's Q1 beat is powered by Skyrizi and Rinvoq, whose strong sales growth offset Humira declines and boosts 2026 guidance.
Realty Income Has Raised Its Dividend 113 Consecutive Times. Here Is Why That Is Not Enough to Own It Right Now
247wallst.com - May 15, 2026
Realty Income (
AbbVie Inc. (ABBV) Presents at Bank of America Global Healthcare Conference 2026 Transcript
seekingalpha.com - May 13, 2026
AbbVie Inc.
The Zacks Analyst Blog NVIDIA, Mastercard, AbbVie, Waterstone and Precipio
zacks.com - May 13, 2026
AI demand and pipeline growth headline top Zacks stock reports on NVIDIA, Mastercard and AbbVie.
How News Affects ABBV Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track ABBV's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked ABBV news questions
- What is the latest ABBV news headline?
- The most recent ABBV headline (May 15, 2026) is "Which Pharma Giant Offers Better Growth: AstraZeneca or AbbVie?". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the ABBV news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What ABBV news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual ABBV options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.